Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer Immunol Immunother. 2020 Jan;69(1):33-42. doi: 10.1007/s00262-019-02434-5. Epub 2019 Nov 28.
Blockading programmed death ligand 1 (PD-L1) shows promising results in patients with some cancers, but not in those with ovarian cancer. V-domain Ig suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint protein that suppresses T cell activation. This study aimed to investigate the expression and clinical significance of VISTA in ovarian cancer as well as its relationship with PD-L1. VISTA and PD-L1 levels in 146 ovarian cancer samples were assessed using immunohistochemistry. We investigated the association between VISTA and other clinicopathological variables, including survival. The associations between the VISTA-encoding C10orf54 gene, other immune checkpoints, and survival were analyzed. VISTA was detected in 51.4% of all samples and 46.6% of PD-L1-negative samples; it was expressed in 28.8%, 35.6%, and 4.1% of tumor cells (TCs), immune cells (ICs), and endothelial cells, respectively. Furthermore, VISTA expression was associated with pathologic type and PD-L1 expression. Moreover, VISTA expression in TCs, but not in ICs, was associated with prolonged progression-free and overall survival in patients with high-grade serous ovarian cancer. The expression of C10orf54 mRNA was associated with prolonged overall survival and immune escape-modulating genes. These results showed that VISTA expression in ovarian tumor cells was associated with a favorable prognosis in patients with high-grade serous ovarian cancer; however, additional studies are required to better understand the expression and role of VISTA in ovarian cancer.
阻断程序性死亡配体 1（PD-L1）在某些癌症患者中显示出有希望的结果，但在卵巢癌患者中则不然。V 结构域免疫球蛋白抑制 T 细胞激活因子（VISTA）是一种新发现的免疫检查点蛋白，可抑制 T 细胞激活。本研究旨在探讨 VISTA 在卵巢癌中的表达及其与 PD-L1 的临床意义。采用免疫组织化学法检测 146 例卵巢癌样本中 VISTA 和 PD-L1 的水平。我们研究了 VISTA 与其他临床病理变量之间的关系，包括生存。分析了 VISTA 编码的 C10orf54 基因与其他免疫检查点和生存之间的关系。在所有样本中，51.4%的样本和 46.6%的 PD-L1 阴性样本中检测到 VISTA；在肿瘤细胞（TCs）、免疫细胞（ICs）和内皮细胞中，VISTA 的表达分别为 28.8%、35.6%和 4.1%。此外，VISTA 的表达与病理类型和 PD-L1 的表达相关。此外，在高级别浆液性卵巢癌患者中，TC 中而非 IC 中 VISTA 的表达与无进展生存期和总生存期延长相关。C10orf54mRNA 的表达与总生存期延长和免疫逃逸调节基因相关。这些结果表明，卵巢肿瘤细胞中 VISTA 的表达与高级别浆液性卵巢癌患者的预后相关，但需要进一步研究以更好地理解 VISTA 在卵巢癌中的表达和作用。
Zotero 插件
